All right. So, so Craig, you know, this is a market focused show, but I do have to talk about the intersection of DC and Wall Street right here. Uh, we saw Democrats win two very high-profile elections in New York and New Jersey.We also saw the Democratic party win a redistricting fight in California. At the same time, this is the one-year anniversary of the president being elected and the longest shutdown in US history. A lot of intersections here.Do you think that those uh elections, were they really a li ...

Reporting favorable Q3 results on Monday evening, Exact Sciences (EXAS)  is an intriguing stock to watch among the Zacks Rank #1 (Strong Buy) list.Recognized as a leader in medical diagnostics, the upside potential for Exact Sciences stock has been lifted by its improved operational and financial performance. Correlating with such, EXAS spiked nearly +4% on Tuesday and is now up more than +20% in 2025.Image Source: Zacks Investment Research High Demand for Exact Sciences Cancer Screening TestsExact Sciences ...

公司概况与市场定位 - 公司专注于癌症预防和早期检测领域，是医疗保健行业的重要参与者 [1] - 公司以创新的Cologuard和Oncotype DX等产品闻名，并获得了医疗界的信任 [1][4] - 公司与其他诊断公司竞争，致力于在癌症诊断领域保持领先地位 [1] 近期股价表现与市场数据 - 罗伯特·W·贝尔德公司于2025年11月4日设定了88美元的目标价，相较于当时72.07美元的股价，潜在上涨空间约为22.11% [2][6] - 公司股票当前价格为70.94美元，当日上涨5.91%或3.96美元，交易区间为67.97美元至72.81美元 [2] - 公司当前交易量为3,962,279股，市值为134.3亿美元 [2][5] - 公司股票过去52周的最高价为72.83美元，最低价为38.81美元 [5] 第三季度财务业绩 - 公司第三季度业绩强劲，超出市场预期，每股收益为0.24美元，远超预期的每股亏损0.07美元 [3][6] - 第三季度销售额达到8.507亿美元，超过预期的8.102亿美元 [3][6] - 基于强劲业绩，公司将2025年全年销售额指引上调至32.2亿美元至32.35亿美元 [3] 增长驱动力与战略重点 - 公司致力于癌症预防和早期检测，其以患者为中心的平台和Cologuard、Oncotype DX等受信任品牌是成功的关键 [4][6] - 现有产品的成功势头推动了增长，并促进了如Cancerguard等新检测产品的开发，从而增强了财务表现 [4] - 强劲的财务表现和创新产品使公司在未来增长中处于有利地位 [5]

TESLA WATCH: Elon Musk Pay Deal In FocusExact Sciences (EXAS) stock surged Tuesday on a broad third-quarter beat that "should allay fears of a market slowdown," an analyst said.The company is well known for Cologuard, a stool-based test that detects colon cancer. Screening revenue, which includes Cologuard tests, grew 22% to $666 million, easily topping forecasts for $637 million. Precision oncology revenue, which includes a breast cancer test, jumped 13% to $184 million. That beat expectations for $173 mil ...

Exact Sciences Corporation (NASDAQ:EXAS) reported better-than-expected third-quarter financial results and raised its FY25 sales guidance above estimates on Monday.Exact Sciences reported quarterly earnings of 24 cents per share which beat the analyst consensus estimate of a loss of 7 cents per share. The company reported quarterly sales of $850.739 million which beat the analyst consensus estimate of $810.178 million.Exact Sciences raised its FY2025 sales guidance from $3.130 billion-$3.170 billion to $3.2 ...

盘前交易概况 - 美国东部时间周二上午7:30 盘前交易出现显著活动 早盘价格波动预示着开盘前的潜在机会 [1] - 对于活跃交易者而言 盘前交易为识别潜在突破 反转或剧烈价格波动提供了先机 [1] - 这些早盘动向通常预示着动能可能延续至常规交易时段 使盘前分析成为交易日的关键部分 [1] 盘前涨幅居前股票 - Denny's Corporation (DENN) 上涨49%至6.16美元 [3] - Cambium Networks Corporation (CMBM) 上涨25%至2.55美元 [3] - Tactile Systems Technology, Inc. (TCMD) 上涨22%至19.35美元 [3] - Upwork Inc. (UPWK) 上涨19%至18.60美元 [3] - Kforce Inc. (KFRC) 上涨12%至27.50美元 [3] - Super Group (SGHC) Limited (SGHC) 上涨12%至11.91美元 [3] - Innovex International, Inc. (INVX) 上涨10%至22.62美元 [3] - Sanmina Corporation (SANM) 上涨9%至154.03美元 [3] - Exact Sciences Corporation (EXAS) 上涨8%至72.69美元 [3] - OTG Acquisition Corp. I Class A Ordinary Share (OTGA) 上涨7%至10.77美元 [3] 盘前跌幅居前股票 - Sarepta Therapeutics, Inc. (SRPT) 下跌40%至14.44美元 [4] - JELD-WEN Holding, Inc. (JELD) 下跌32%至2.81美元 [4] - Ichor Holdings, Ltd. (ICHR) 下跌29%至16.05美元 [4] - Insperity, Inc. (NSP) 下跌27%至32.50美元 [4] - Prelude Therapeutics Incorporated (PRLD) 下跌22%至3.08美元 [4] - Forward Industries, Inc. (FORD) 下跌20%至11.11美元 [4] - Navitas Semiconductor Corporation (NVTS) 下跌18%至10.03美元 [4] - Diginex Limited (DGNX) 下跌17%至19.51美元 [4] - Atlas Energy Solutions Inc. (AESI) 下跌16%至10.58美元 [4] - Chijet Motor Company, Inc. (CJET) 下跌15%至3.24美元 [4]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Exact Sciences (NasdaqCM:EXAS) Q3 2025 Earnings Call November 03, 2025 05:00 PM ET Company ParticipantsKevin Conroy - Chairman and CEODerek Leckow - Head of Investor RelationsAaron Bloomer - CFOConference Call ParticipantsLuke Sergott - AnalystTycho Peterson - AnalystBill Bonello - AnalystDan Brennan - AnalystAndrew Brackmann - AnalystVijay Kumar - AnalystMike Ryskin - AnalystSubbu Nambi - AnalystCatherine Schulte - AnalystBrad Bowers - AnalystJack Meehan - AnalystMark Massaro - AnalystKyle Mikson - Analyst ...

Exact Sciences (NasdaqCM:EXAS) Q3 2025 Earnings Call November 03, 2025 05:00 PM ET Company ParticipantsKevin Conroy - Chairman and CEODerek Leckow - Head of Investor RelationsAaron Bloomer - CFOConference Call ParticipantsLuke Sergott - AnalystTycho Peterson - AnalystBill Bonello - AnalystDan Brennan - AnalystAndrew Brackmann - AnalystVijay Kumar - AnalystMike Ryskin - AnalystSubbu Nambi - AnalystCatherine Schulte - AnalystBrad Bowers - AnalystJack Meehan - AnalystMark Massaro - AnalystKyle Mikson - Analyst ...